Kathryn Scott Osler, The Denver Post
Patrick Mahaffy, President and Chief Executive Officer at Clovis Oncology in Boulder. Getting your player ready...
By Shay Castle, Daily Camera
Boulder-based Clovis Oncology is pursuing a $205 million stock offering to fund the marketing and sales of its recently approved ovarian cancer drug, rucaparib.
The drug, now branded as Rubraca, received accelerated approval from the Food and Drug Administration in mid-December for use in patients with a specific gene mutation that have already undergone two or more rounds of chemotherapy.
In clinical trials that concluded in the fall, 54 percent of patients responded favorably to the rucaparib treatment.
To fund the sales and marketing of the drug, Clovis is offering 5 million shares of common stock at $41 per share, the company announced Tuesday.
.